Omega Therapeutics

Omega Therapeutics, Inc. engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of DNA-sequence-targeting and mRNA-encoded therapeutics. It offers its product under the OMEGA platform. The company was founded by Noubar B. Afeyan and David Berry on July 13, 2016 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11.

Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.50 per share a year ago.

Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.

Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

Omega Therapeutics (OMGA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024. The poster will feature new preclinical data that demonstrate the ability of Omega's programmable epigenomic controllers (ECs) to pre-transcriptionally upregulate gene expression across a diverse set of genes, offering a broad range of potential therapeutic applications.

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting

After losing some value lately, a hammer chart pattern has been formed for Omega Therapeutics (OMGA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller (MYC-EC) in models of EGFR inhibitor (EGFRi)-resistant non-small cell lung cancer (NSCLC) at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 – 10. The Company also presented preclinical data validating a novel pharmacodynamic biomarker assay for monitoring on-target engagement and activity of its clinical-stage EC candidate, OTX-2002.

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control

Omega Therapeutics (OMGA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know

Novo Nordisk

Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung cancer, and obesity. Omega Therapeutics has signed a collaboration with Novo Nordisk to develop a drug for obesity management, validating the potential of its platform.

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.64 per share a year ago.

Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the fourth quarter and full year ended December 31, 2023, and a strategic prioritization initiative to focus resources on near-term milestones to support long-term shareholder value.

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, California, April 5 – 10, 2024. The first poster will feature preclinical data validating a novel method for evaluating epigenomic controller (EC) target engagement using noninvasive liquid biopsies. Additionally, the Company will present new preclinical data supporting a MYC-targeting EC approach in models of non-small cell lung cancer (NSCLC) resistant to EGFR inhibitors.

Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024

Demand for weight loss drugs and related stocks is high, with companies like Novo Nordisk and Eli Lilly experiencing significant returns. Omega Therapeutics may be a speculative investment opportunity in the weight loss drug market as it recently entered into a collaboration with Novo Nordisk. While initially spiking, OMGA's reaction to news of this collaboration has been relatively muted compared to NVO.

Omega Therapeutics: The Next Weight Loss Drug Runner

Altimmune

Viking Therapeutics

Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. Look at obesity drug stocks, like Eli Lilly (NYSE: LLY ) for example.

The 3 Best Biotech Stocks to Buy in January 2024

Using Omega's (OMGA) proprietary technology platform, Novo Nordisk (NVO) intends to develop a novel therapeutic for obesity, which will enhance the body's metabolism activity to burn excess fats.

Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk

Omega Therapeutics (NASDAQ: OMGA ) stock is rising higher on Thursday after the company announced a research collaboration agreement with Novo Nordisk (NYSE: NVO ). The collaboration between the two companies will focus on developing an obesity management treatment.

Why Is Omega Therapeutics (OMGA) Stock Up 111% Today?

Omega Therapeutics shares surged more than 100% after it was announced it is partnering with Danish healthcare company Novo Nordisk (NYSE:NVO) to develop novel treatment approaches for cardiometabolic diseases. Novo Nordisk (NYSE:NVO) said that its collaboration with Omega will develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.

Omega Therapeutics shares surge on obesity collaboration with Novo Nordisk

Bagsværd, Denmark, Cambridge, Mass., and Somerville, Mass. 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity's platform to develop a small molecule therapy against this disease.

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 9:45 a.m. PT (12:45 p.m. ET).

Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023, at 9:30 a.m. ET.

Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 12:00 p.m. ET.

Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference

First-ever demonstration of sustained pre-transcriptional upregulation of gene expression by an epigenomic controller in both in vitro and in vivo models of liver fibrosis

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent Company progress.

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 12:30 p.m. GMT (7:30 a.m. ET).

Omega Therapeutics to Participate in The Jefferies London Healthcare Conference

Coordinated modulation of epigenetic profile of CXCL1-8 genes with corresponding downregulation of gene expression and protein levels, and inhibition of immune cell recruitment, shown in multiple models of inflammatory disease

News for Omega Therapeutics Stock (OMGA)